<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>DHODH İnhibitörleri &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/dhodh-inhibitorleri/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 19 Jan 2026 07:57:47 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>DHODH İnhibitörleri &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>BCOR Mutations Reveal Target for AML Treatment</title>
		<link>https://bioengineer.org/bcor-mutations-reveal-target-for-aml-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jan 2026 07:57:47 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[DHODH İnhibitörleri]]></category>
		<category><![CDATA[Hedefli AML Tedavisi]]></category>
		<category><![CDATA[İşte 5 uygun etiket (virgülle ayrılmış): **BCOR Mutasyonları]]></category>
		<category><![CDATA[Kişiselleştirilmiş onkoloji]]></category>
		<category><![CDATA[Terapötik Açık** **Açıklama:** 1. **BCOR Mutasyonları:** Makalenin temel konusu ve araştırmanın odak n]]></category>
		<guid isPermaLink="false">https://bioengineer.org/bcor-mutations-reveal-target-for-aml-treatment/</guid>

					<description><![CDATA[In the light of groundbreaking research published in the field of hematology, scientists have unveiled critical insights into acute myeloid leukemia (AML), particularly in relation to mutations within the BCOR gene. This discovery has potentially significant implications for treatment strategies utilizing DHODH inhibition. BCOR mutations have been recognized as a pivotal factor that characterizes a [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318190</post-id>	</item>
	</channel>
</rss>
